Quite a lot of the low-hanging fruit from pharma has already been picked. The modern business model for pharma involves coming up with a patentable new drug that does the same thing as an older drug that's now out of patent and available for manufacture as a generic.

Making pharmaceuticals subservient to the whimsy of the stock market is a bad idea. It introduces incentive distortions where none should be.